Indication
Dyspepsia prevention
Dyspepsia prevention refers to the prophylactic management aimed at averting the onset or recurrence of upper gastrointestinal discomfort and indigestion symptoms in susceptible patient populations. Read more about Dyspepsia prevention
113 drugs 93 manufacturers
Drugs that treat it
Common Dyspepsia prevention therapies.
FAMOTIDINE (famotidine/PF)
FAMOTIDINE IN 0.9 % NACL (famotidine in 0.9 % sodium chloride)
HEARTBURN PREVENTION (famotidine)
PEPCID AC MAXIMUM STRENGTH (famotidine)
ACID REDUCER (FAMOTIDINE) (famotidine)
ACID-PEP (famotidine)
ACID REDUCER (FAMOTIDINE) (famotidine)
ACID REDUCER (FAMOTIDINE) (famotidine)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonDyspepsia prevention refers to the prophylactic management aimed at averting the onset or recurrence of upper gastrointestinal discomfort and indigestion symptoms in susceptible patient populations.
It targets disorders affecting the gastroduodenal system, notably in individuals at risk due to mucosal-irritating pharmacotherapies—such as nonsteroidal anti-inflammatory drugs—or underlying peptic ulcer disease and functional gastrointestinal disorders.
The clinical state is characterized by potential epigastric burning or pain, postprandial fullness, early satiety, nausea, and bloating.
Pathophysiologically, preventive interventions target mechanisms such as excess gastric acid secretion, impaired gastroduodenal mucosal barrier defenses, gastroduodenal dysmotility, and visceral hypersensitivity.
- nih.gov
Dyspepsia prevention refers to the prophylactic management aimed at averting the onset or recurrence of upper gastrointestinal discomfort and indigestion symptoms in susceptible patient populations
- nih.gov
Dyspepsia prevention refers to the prophylactic management aimed at averting the onset or recurrence of upper gastrointestinal discomfort and indigestion symptoms in susceptible patient populations
- aafp.org
It targets disorders affecting the gastroduodenal system, notably in individuals at risk due to mucosal-irritating pharmacotherapies—such as nonsteroidal anti-inflammatory drugs—or underlying peptic ulcer disease and functional gastrointestinal disorders
- nih.gov
It targets disorders affecting the gastroduodenal system, notably in individuals at risk due to mucosal-irritating pharmacotherapies—such as nonsteroidal anti-inflammatory drugs—or underlying peptic ulcer disease and functional gastrointestinal disorders Pathophysiologically, preventive interventions target mechanisms such as excess gastric acid secretion, impaired gastroduodenal mucosal barrier defenses, gastroduodenal dysmotility, and visceral hypersensitivity
- nih.gov
The clinical state is characterized by potential epigastric burning or pain, postprandial fullness, early satiety, nausea, and bloating
- nih.gov
The clinical state is characterized by potential epigastric burning or pain, postprandial fullness, early satiety, nausea, and bloating Pathophysiologically, preventive interventions target mechanisms such as excess gastric acid secretion, impaired gastroduodenal mucosal barrier defenses, gastroduodenal dysmotility, and visceral hypersensitivity
- clevelandclinic.org
Pathophysiologically, preventive interventions target mechanisms such as excess gastric acid secretion, impaired gastroduodenal mucosal barrier defenses, gastroduodenal dysmotility, and visceral hypersensitivity
Personalize your experience
Follow Dyspepsia prevention and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.